345 Park Avenue South

Blue

News & Insights

Your Home in NYC

Cure Founders Pass Membership Benefits 03 Tab Bar Image

Dark Blue

Apply for Membership

Where Healthcare Innovators Connect

Magenta

Attend An Event

Accelerating Advances in Health

Green

About

Contact us

### About

Ryan Flinn has been a professional storyteller for more than 25 years, across both journalism and communications. He revels in translating complex science and technology news into meaningful articles.

### Experience

Flinn started his career as a journalist, working for a daily newspaper, a news wire service and eventually ending up at Bloomberg News. There, he covered breaking news, technology, biotech and wine. After more than a decade as a reporter, he changed careers and started advising companies on communications strategy. He worked at an agency before joining J&J Innovation, where he helped startups and dealmakers promote their science. After J&J, Flinn led all communications for two companies focused on the biotech space. In 2023, he started his own firm, In Like Flinn Communications, and divides his time between advising companies and freelance writing.  His articles have been published in *The New York Times*, *The San Francsico Chronicle*, *Businessweek*, *Evidence-Based Oncology*, *Managed Healthcare Executive* and Cure. He is the AI correspondent for BiotechTV and publishes a weekly newsletter, AI Rx, on how AI is transforming healthcare.

### Education

Flinn earned his B.A. in classics from the College of the Holy Cross in Worcester, MA.


Contributing Writer

Fewer blockbuster acquisitions, a surge of AI partnerships, and uneven regulatory signals defined this year’s JP Morgan Healthcare Conference.

JPM26 Recap: AI Takes Center Stage While Pharma Waits and Policy Signals Blur

These five healthcare-focused funds raised or launched capital in late 2025, with $4.5B to deploy across biotech, medtech, and digital health, including in the US.

5 Healthcare Funds Deploying $4.5 Billion Into Biotech and Medtech Right Now

In a candid conversation with Cure, Dr. Jay Bhattacharya talked about affordable manufacturing, gaps in today’s research system, rebuilding trust in science, and where he hopes entrepreneurs will step in.

NIH Chief Says Lowering Therapy Costs Is the Next Big Frontier for Entrepreneurs

CMS’ new payment rate for Eko Health’s AI-assisted cardiac exam signals growing federal support for AI in routine care, as more tools secure coverage and lawmakers push for broader reimbursement pathways.

Medicare Approves First Wave of AI Heart Screening Tools

The FDA granted a second approval to Syndax’s menin inhibitor Revumenib, expanding its use to a larger genetic subset of acute myeloid leukemia and marking a rare back-to-back win nearly 20 years after the science first emerged.

Thumbnail laboratory pipette test tube research November 2025 - Image

A Targeted Leukemia Drug Just Won Two FDA Approvals in Under a Year

FDA's top leadership just announced a fast-track approval pathway for personalized rare-disease therapies, built around clear biologic mechanisms, early patient improvement, and platform-based evidence from just a few treated cases.

FDA Headquarters on the White Oak campus in Silver Spring, Maryland.

FDA Signals New Fast Track for Personalized Rare-Disease Therapies

FDA veteran Richard Pazdur is taking over the agency’s drug division after months of turmoil. Here’s how his leadership could influence drug reviews, evidence standards, and the regulatory landscape for biotech startups.

What Richard Pazdur’s New Role Means for FDA Drug Reviews—and How It Might Shape Biotech

TrumpRx and MFN pricing deals are reshaping how biotech startups market medicines, set prices, and plan U.S. manufacturing. Here’s what founders need to know before the 2026 rollout.

Ozempic Pills Drugs SS2440411479

TrumpRx Is Rewriting Biotech’s Playbook—Here’s How Startups Should Respond

Siren Biotechnology CEO Nicole Paulk shares how her team raised $4.2 million from more than 1,600 investors, breaking biotech norms with a public crowdfunding campaign—and the lessons she learned along the way.

How a Biotech CEO Turned 1,600 Everyday Investors Into Backers—and Raised $4 Million Image

How a Biotech CEO Turned 1,600 Everyday Investors Into Backers—and Raised $4 Million

Woodcock, who is credited with shaping nearly every major regulatory advancement in modern medicine, offers advice for startups navigating FDA regulation today.

5 Tips from Former FDA Commissioner Janet Woodcock on How To Win Over Regulators

5 Tips from Former FDA Commissioner Janet Woodcock on How to Win Over Regulators

Fresh funds arrive as biotech's share of startup dollars hit a 20-year low. Here are the companies ready to deploy $4 billion for drug discovery, medical devices, and digital health companies.

7 Venture Funds Deploying $4 Billion for Biotech This Fall

From one-time gene fixes to new cancer drugs, here are the breakthroughs and decisions to watch for in Q4.

The Fall Biotech Watchlist: 9 High-Stakes Decisions Ahead

The October 1 shutdown leaves Medicare and Medicaid checks intact but halts new FDA filings, NIH grants, and key Medicare programs, potentially creating delays and funding gaps that could hit healthcare startups.

10 Ways the Government Shutdown Could Affect Your Healthcare Startup

The agency's decision to ease evidence requirements for a psoriasis drug application could lower costs and expand access to copycat biologic medicines.

FDA's Latest Move Could Pave the Way for Cheaper Complex Medicines

After decades of little change, a record number of late-stage clinical trials is reshaping the landscape of allergy medicine.

Allergy Drugs are Drawing a Surge of Trials and Fresh Funding

As pharmaceutical giants pour billions into new U.S. labs and factories, demand rises for equipment suppliers and workforce training.

Drugmakers’ Record Factory Expansions Fuel a New Biotech Supply Boom Image

Drugmakers’ Record Factory Expansions Fuel a New Biotech Supply Boom

Major shifts in Medicare could result in millions of patients losing access to virtual care, with a ripple effect likely impacting private insurers and state Medicaid programs as well.

Telehealth In Turmoil—Here's All That's Changing On October 1  Image

Telehealth In Turmoil—Here's All That's Changing On October 1

More than one-third of all new life sciences lab construction in the U.S. is taking place outside the traditional power centers, ushering a new era of geographic growth.

Biotech's New Hubs Are Booming—Here Are the Places Investors and Manufacturers Are Betting On Image

Biotech's New Hubs Are Booming—Here Are the Places Investors and Manufacturers Are Betting On

Biotech companies are reducing head counts and offices as AI and automation take on research, regulatory and operational tasks, lowering costs and opening opportunities for growth.

How AI is Shrinking Biotech Workplaces Image

How AI is Shrinking Biotech Workplaces

NIH's new framework for gold standard science promises improved biomedical research quality, but critics fear reforms could centralize control and politicize science while raising concerns for innovation and long-term funding priorities.

NIH's 'Gold Standard' Research Rules Plan Draws Skepticism and Political Concerns

Prescriptions are climbing fastest among younger men, spurring startups and incumbents to rethink testosterone therapy with innovative access models and next-generation treatments.

Startups Disrupt Testosterone Therapy Market as Younger Men Fuel Demand

Consumer Tech Turns to AI to Compete as Health Companies

A surge of AI-first innovations is pushing electronic health records from static record keeping into dynamic platforms, unlocking new opportunities for startups to plug into clinical and revenue workflows.

AI Recasts EHRs as Growth Engines for Health Tech

CureWise founder Steve Brown turned his own cancer scare into a platform for patients seeking more precise answers

How Missed Cancer Diagnosis Led Founder to Build AI Platform for Patients

A new Milken Institute report outlines how innovators can close the gap between lifespan and healthy years, and tap a fast-growing global market for dementia solutions.

Startups Eye $2.8 Trillion Dementia Challenge as Healthspan Gap Widens

A new federal law cements first-dollar coverage for telehealth under high-deductible health plans, unlocking a massive market for digital health companies while setting the stage for the next wave of policy debates over access and innovation.

Congress Permanently Opens First-Dollar Telehealth to 60 Million Americans

A sweeping new CMS initiative, backed by the White House, will create a secure, interoperable app store for Medicare, offering startups unprecedented access to health data and a massive user base.

Startups Get Early Shot at Building Tools for U.S. Health Data Network Image 16-9

Medicare's New App Store Opens a $1 Trillion Market to Health Startups

Endpoints that reflect real-world value to patients can help startups improve enrollment and retention, and boost commercial success.

How Patient-Centered Trials Can Improve Biotech ROI

As Series B capital gets harder to secure, companies raise more in earlier rounds to reach value milestones.

‘Barbell Effect’ Reshapes Funding for Healthcare Entrepreneurs Image HERO

‘Barbell Effect’ Reshapes Funding for Healthcare Entrepreneurs

Newly released FDA complete response letters offer healthcare entrepreneurs insight into why drug applications fail and how to avoid the same mistakes.

What Startups Can Learn from FDA ‘No’ Letters

Open-source biological datasets Boltz-2 and Tahoe-100M are helping resource-strapped healthcare entrepreneurs and academic scientists accelerate drug discovery using AI but without the high data costs.

How Public Data Fuels the Next Wave of Drug Innovation

Faced with shrinking budgets, academic and industry life science researchers are making strategic partnerships their top priority.

Why Scientists and Startups are Doubling Down on Partnerships in 2025

CMS’s new Cell and Gene Therapy Access Model allows states to offer sickle cell gene therapies through federally negotiated contracts, reshaping CGT market for startups and rare disease therapeutics.



New Federal Program Expands Access to Gene Therapies for Sickle Cell and More

Despite a historic slump in biotech IPOs and venture funding, three women-led exits break through in a tough 2025.

Startups Face Bleak Funding While Women-Led Firms Score Rare M&A Wins

AI startups attracted most of the new digital health money in the first half of 2025, as investors focus on scaling proven technologies.

AI-Powered Companies Dominate 2025 Digital Health Funding

The Supreme Court’s decision upholding preventive care coverage under the Affordable Care Act signals a stable, growing market for healthcare startups and entrepreneurs.

Supreme Court Upholds Preventive Care Mandate — What It Means for Healthcare Innovation

The EU’s top health official said reforms will make Europe more attractive for drug developers as FDA changes create industry uncertainty.

Europe Makes Bold Bid to Attract Biotech Amid FDA Uncertainty

In a move praised by advocates and physicians, the FDA eliminated post-treatment safety restrictions for CAR T therapies based on real-world data, potentially setting a precedent for regulatory flexibility for cell and gene therapies.

FDA Lifts Key Barriers to Immunotherapies Access, Signaling Regulatory Shift

The shortage of anti-obesity medications is sending patients to gray markets while healthcare innovators look for longer-term solutions beyond of GLP-1s.

How Entrepreneurs are Looking Beyond GLP-1s for Obesity Innovations

NYU Langone’s Marc Sedam shares how, amid sweeping federal cuts to scientific research, some U.S. universities are quietly rewriting the funding playbook for moving discoveries from lab to market.

Marc Sedam NYU Langone Thumbnail Image

Universities Step Up as Translational Funders Amid NIH Uncertainty

CEO Mary Beth Cicero says women’s health startups face hurdles even with novel ideas and real-world demand.

Mary Beth Cicero 3 Daughters Thumbnail Image

Breakthrough IUD Faces Familiar Funding Barrier in Women’s Health

Healthcare industry executives at BIO paint a picture of optimism for the sector's future amid policy changes and technological disruptions.

6 executives Betty Woo, PhD  and Daniella Cramp image

6 Executives on How Resilience, Not Retreat, Defines the Healthcare Year Ahead

Ernst & Young’s latest report shows biotech investors remain cautious in 2025, but innovation and partnerships offer path for a rebound.

Biotech Seeks Turnaround as Investors Focus on Fundamentals

Despite reductions and restructuring, the FDA is strong and on track to meet its goals, FDA Commissioner Martin Makary, MD, said at BIO.

FDA Commissioner Pushes Aggressive Overhaul Amid Biotech Uncertainty

The FDA held a listening session with cell and gene therapy scientists, advocates and entrepreneurs to learn how to improve the regulatory process.

FDA Industry Panel Pushes for Faster Cell and Gene Therapy Reviews

The FDA is setting new priorities designed to bring innovative healthcare products to market faster, though concerns about political interference at federal science agencies complicate the picture.

FDA Shares New Priorities and ‘Proactive’ Approach to Working with Developers

A new wave of studies and startups are pushing blood-based cancer tests into clinics, yet access and cost challenges remain.

Blood Tests Offer Earlier, Personalized Detection of Cancer’s Return image

Blood Tests Offer Earlier, Personalized Detection of Cancer’s Return

The MAHA Commission, chaired by HHS Secretary Robert F. Kennedy, Jr., critiques current U.S. policies and spotlights four drivers of “the sickest generation," including industry influence, overmedicalization, environment exposures and systemic failures.

‘MAHA’ Reports U.S. Children’s Health Issues, Calls for Strategic Realignment

The U.S. faces a tipping point in science and innovation, with top experts urging bold reforms to reverse declines in research funding, talent, and global influence.

Reclaiming U.S. Scientific Leadership: A Wake-Up Call for Innovators

The FDA is moving swiftly to overhaul its drug and device review process with the help of AI, announcing plans to implement these tools across every agency center by the end of June.

FDA Sets Aggressive AI Rollout to Speed Drug Reviews

New reports from Jefferies and J.P. Morgan offer a split-screen view of biotech’s rough start and its potential recovery in the second half of 2025.

Best or Worst of Times for U.S. Healthcare? Analysts Split on Outlook

While the biopharma market continues to struggle financially, companies focused on digital health and AI are gaining traction with funders.

How AI-Powered Apps Opened $5.3B in New Deals for Healthcare Entrepreneurs in Q1 2025

Harvard and MIT respond to federal crackdown on international students and research funding.

Trump Administration Action Against Harvard Sparks Backlash, Scientific Talent War

From AI-powered reproductive health tools to WhatsApp care help women worldwide, despite continued social barriers to use and financial challenges for FemTech developers.

Digital Health Tools Advance Women’s Autonomy, But Gaps Remain

Former President Biden’s metastatic prostate cancer diagnosis highlights a new era of precision medicine, as healthcare startups and oncologists develop more accurate diagnostics and less invasive treatments to combat the disease’s deadliest forms.

Biden’s Diagnosis Brings Urgency to Prostate Cancer Innovation

A growing number of state legislatures are proposing laws that would limit and even criminalize mRNA medicines, just as the technology is starting to provide new approaches to diseases ranging from ALS to MD and from pancreatic cancer and HIV/AIDS. 

Proposed mRNA Bans Alarm Scientists and Startups

Lux Capital's initiative offers money, mentorship and migration pathways to keep scientific discoveries alive amidst rising international competition for America's innovators.

Lux Capital Launches $100M ‘Helpline’ for U.S. Scientists

The executive order could harm innovative research and development, but could also alleviate financial burdens on patients.

Trump’s Drug Pricing Executive Order Splits Biopharma Leaders

As biopharmas report first quarter earnings, executives are being asked to respond to the Trump administration’s many changes to the business environment, regulatory scene and domestic manufacturing.

Drugmakers Brace for Trump-Era Shifts on Tariffs, Manufacturing and Regulation

Small businesses can secure non-dilutive funding through the NIH SBIR program to develop healthcare technologies and services that overcome barriers to care for populations experiencing health disparities.

NIH Offers $10 Million in Grants for Startups Tackling Health Disparities

Three key takeaways from AdvaMed's new report provide suggestions for companies developing new medical technologies that rely on AI.

How AI MedTech Entrepreneurs Can Tackle Policy, Payment and Privacy Pitfalls

The FDA’s new plan to phase out many animal studies is already reshaping drug R&D as startups and pharma teams adopt digital and human-cell platforms.

FDA Roadmap Accelerates High-Tech Alternatives to Animal Tests

A public garden opening next month in San Francisco pays tribute to young people who died of metastatic breast cancer. The first such U.S. memorial also exposes a stubborn truth: new drugs have not erased the disease’s deadliest form.

‘They Keep Dying Young’: Memorial Garden to Honor Lives Lost to Breast Cancer

Companies and medical centers are increasingly looking at how inserting computer chips in the brain can help patients recover from a variety of conditions, in a market expected to hit $12 billion in the next decade.

From Thoughts to Reality – the Rise of Brain-Computer Interface Tech 

Ambient AI scribes are rapidly transforming healthcare practices and reportedly significantly reducing physician burnout while maintaining documentation quality, though financial returns remain unclear.

Doctors Embrace AI Scribes as Solution for Burnout

Scientists are scrambling to manage surging costs as President Trump's sweeping tariffs on imported laboratory equipment begin to bite.

Trump Tariffs Strain Science Research Budgets for Lab Equipment

A new analysis finds that cell and gene therapies are twice as likely to win FDA approval, but commercial uptake remains slow due to cost, infrastructure and delivery challenges.

Despite Twice the FDA Success Rate, Gene Therapies Still Miss Patients-Thumbnail Image

Despite Twice the FDA Success Rate, Gene Therapies Still Miss Patients

A new federal report warns that America’s biotech leadership is slipping behind China, calling for a $15 billion investment plan to boost innovation and protect national interests.

U.S. Falling Behind in Biotech, Government Warns

U.S. Urged to Invest $15 Billion in Biotech to Counter China

While biopharma struggles attracting investors, AI, non-opioid pain medications, cell and gene therapies and metabolic diseases are still finding funding. 

How AI Moonshots Nailed Biotech Funding in Bleak Quarter

Healthcare’s growing reliance on generative AI has opened the door to new cybersecurity risks that are easy to miss until it’s too late.

How Cybercriminals Increasingly Exploit Healthcare’s ChatGPT image

How Cybercriminals Increasingly Exploit Healthcare’s ChatGPT

While the Trump administration slashes government grants to early-stage research that has played a critical role in drug development, researchers provide advice on how to influence government representatives to push back.

Mayhem, Destruction and Biomedical Tumult from Trump Cuts

Nvidia’s Kimberly Powell showcases how AI powers exponential levels of biological intelligence to reshape healthcare innovation and the future of medicine.

Nvidia Unveils AI Agents for Labs, Clinics and Trials image

Nvidia Unveils AI Agents for Labs, Clinics and Trials

At Nvidia’s AI-focused technology conference, scientists, startups and life science luminaries discussed the next wave of innovation to hit healthcare.

AI Adoption in Healthcare Comes Fast at Nvidia GTC 2025 image

AI Adoption in Healthcare Comes Fast at Nvidia GTC 2025

Montai Therapeutics, led by former Google executive Margo Georgiadis, is using AI to transform drug discovery by identifying and optimizing natural compounds, expanding access to small-molecule treatments for chronic diseases.

How an Unconventional CEO is Reimagining Drug Discovery

Beam’s clinical trial is the first to report evidence that a base-editing therapy can rewrite a patient’s genetic code to correct a disease-causing mutation. This milestone now creates a path forward to treat other genetic diseases.

How Beam Therapeutics Success Could Drive Precision Medicine image

How Beam Therapeutics Success Could Drive Precision Medicine

Biotech wasn’t sure what to expect under a second Trump term. Industry leaders and analysts predict policy shifts could benefit innovation and drug pricing reform.

Biotech’s Surprising Policy Boost Under Trump image

Biotech’s Surprising Policy Boost Under Trump

The trend of mid-level prescribers increasing scrips means expanded access for patients and new go-to-market strategies for drug developers.

Why More Patients Get Meds from Mid-Level Prescribers 

Big drugmakers and direct-to-consumer clinics are expanding obesity care with new GLP-1s, cheaper self-pay options and new therapies that may transform this rapidly evolving market.

Obesity Drug Market Charts New Course for Patients, Investors image

Obesity Drug Market Charts New Course for Patients, Investors

This week's healthcare innovation news focuses on rare diseases: AI speeds diagnoses, variants of 69 genes are newly linked to diseases, GDF15 marker improves mitochondrial disorder testing, and annual FDA-NIH Rare Disease Day postponed.

This Week in Healthcare innovation image

AI, New Gene Variants Poised to Improve Rare Disease Testing

The Inflation Reduction Act's price negotiation rules are reshaping rare disease drug development strategies, impacting both large and small biotech companies.

thumbnail_syringe_vial_pills_GTY1064970292

Rare Disease Startups Face a Surprising Strategic Dilemma

Altitude Lab’s $250,000 grants come as NIH funding uncertainty threatens approximately 1,500 health-related startups nationwide, potentially impacting America's leadership in biomedical innovation and the associated economic benefits.

Racing to Cures: The Cure U.S.-China Biotech Competitiveness Scorecard

What Makes an Institution Innovative? A Cure Original Report

Your Home in NYC

Where Healthcare Innovators Connect

Accelerating Advances in Health

Ryan Flinn

100 Articles by Ryan Flinn